UBS AM
GTHX

UBS AM’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

UBS AM’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-39,600
Closed -$106K – 2703
2023
Q2 		$106K Hold
39,600
– – ﹤0.01% 2641
2023
Q1 		$106K Buy
39,600
+27,300
+222% +$131K ﹤0.01% 2641
2022
Q4 		$66.8K Buy
+12,300
New +$103K ﹤0.01% 2507
2022
Q2 		– Sell
-41,011
Closed -$312K – 2793
2022
Q1 		$312K Hold
41,011
– – ﹤0.01% 2584
2021
Q4 		$419K Hold
41,011
– – ﹤0.01% 2614
2021
Q3 		$550K Hold
41,011
– – ﹤0.01% 2463
2021
Q2 		$900K Buy
41,011
+2,899
+8% +$64.4K ﹤0.01% 2265
2021
Q1 		$917K Buy
38,112
+4,222
+12% +$98.1K ﹤0.01% 2132
2020
Q4 		$610K Buy
33,890
+8,647
+34% +$129K ﹤0.01% 2221
2020
Q3 		$292K Buy
25,243
+1,378
+6% +$22.7K ﹤0.01% 2310
2020
Q2 		$579K Sell
23,865
-187,248
-89% -$3.1M ﹤0.01% 2055
2020
Q1 		$2.33M Sell
211,113
-41,123
-16% -$768K ﹤0.01% 1346
2019
Q4 		$6.67M Buy
252,236
+7,840
+3% +$183K ﹤0.01% 1084
2019
Q3 		$5.57M Sell
244,396
-4,886
-2% -$154K ﹤0.01% 1164
2019
Q2 		$7.64M Buy
249,282
+113,294
+83% +$2.39M 0.01% 1042
2019
Q1 		$2.26M Buy
135,988
+711
+0.5% +$13.5K ﹤0.01% 1460
2018
Q4 		$2.59M Sell
135,277
-14,639
-10% -$548K ﹤0.01% 1322
2018
Q3 		$7.84M Buy
+149,916
New +$8.17M 0.01% 996

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS AM's GTHX Position: Q3 2023 in Review

UBS AM sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2023, closing a stake of 39,600 shares — an estimated $106K sold.

UBS AM first reported a position in GTHX in Q3 2018 and held it in 18 quarters. The position peaked at $7.84M in Q3 2018. 72 funds tracked by Wall St. Rank hold GTHX as of Q3 2023.

  • UBS AM reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 39,600 G1 Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $106K.
  • UBS AM first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 18 quarters.
  • UBS AM's G1 Therapeutics, Inc. Common Stock position peaked at $7.84M in Q3 2018.
  • 72 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.